Mura Paola, Zerrouk Naima, Mennini Natascia, Maestrelli Francesca, Chemtob Chantal
Dipartimento di Scienze Farmaceutiche, Facoltà di Farmacia, Università di Firenze, Via Gino Capponi 9, 50121 Firenze, Italy.
Eur J Pharm Sci. 2003 May;19(1):67-75. doi: 10.1016/s0928-0987(03)00068-x.
The solubilizing and amorphizing properties toward naproxen (a poorly water-soluble antiinflammatory drug) of chitosan, an emerging pharmaceutical biopolymer, have been investigated. Solid binary systems at different drug/polymer ratios have been prepared according to different techniques (mixing, cogrinding, kneading, coevaporation) using chitosan at low (CS-L(w)) and medium (CS-M(w)) molecular weight, and tested for dissolution properties. Drug-carrier interactions were investigated in both the liquid and solid state, by phase solubility analysis, differential scanning calorimetry, X-ray powder diffractometry, FT-IR spectroscopy, and scanning electron microscopy. Drug dissolution parameters improved with increasing the polymer amount in the mixture, reaching the highest values at the 1:9 (w/w) drug/polymer ratio, and CS-L(w) was more efficacious than CS-M(w). Cogrinding was the most effective technique, showing the strongest amorphizing effect toward the drug and enabling an increase of more than ten times its relative dissolution rate. Coground mixtures at 3:7 (w/w) drug/polymer ratio were able to give directly compressed tablets which maintained unchanged the improved drug dissolution properties. Enhancer dissolution properties combined with its direct compression feasibility and antiulcerogenic action make CS-L(w) an optimal carrier for developing fast-release oral solid dosage forms of naproxen.
壳聚糖是一种新兴的药用生物聚合物,已对其增溶和无定形化特性(针对难溶性抗炎药物萘普生)进行了研究。使用低分子量(CS-L(w))和中等分子量(CS-M(w))的壳聚糖,根据不同技术(混合、共研磨、捏合、共蒸发)制备了不同药物/聚合物比例的固体二元体系,并测试了其溶出特性。通过相溶解度分析、差示扫描量热法、X射线粉末衍射法、傅里叶变换红外光谱法和扫描电子显微镜,对药物-载体相互作用进行了液态和固态研究。药物溶出参数随混合物中聚合物含量的增加而改善,在药物/聚合物比例为1:9(w/w)时达到最高值,且CS-L(w)比CS-M(w)更有效。共研磨是最有效的技术,对药物显示出最强的无定形化作用,并使其相对溶出速率提高了十多倍。药物/聚合物比例为3:7(w/w)的共研磨混合物能够直接压片,且能保持改善后的药物溶出特性不变。增溶特性、直接压片可行性及其抗溃疡作用相结合,使CS-L(w)成为开发萘普生速释口服固体剂型的最佳载体。